Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes

24 Apr 2019

Abstract excerpt

Importance: Genetic and epidemiologic data suggest that lipoprotein(a) (Lp[a]) is one of the strongest genetically determined risk factors for coronary heart disease (CHD). Specific therapies to lower Lp(a) are on the horizon, but the required reduction of Lp(a) to translate into clinically relevant lowering of CHD outcomes is a matter of debate. Objective: To estimate the required Lp(a)-lowering effect size that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atherosclerosis and Cardiovascular Diseases
Share to Genetic Associations and Epidemiology
Share to Lipoproteins and Cardiovascular Health

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31017618
DOI: 10.1001/jamacardio.2019.1041

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease OutcomesPMID 31017618Read ↗

Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis.Semantic proximity Read ↗

Evaluating genetically-predicted causal effects of lipoprotein(a) in human diseases: a phenome-wide Mendelian randomization studySemantic proximity Read ↗

Sex-Specific Associations of Genetically Predicted Circulating Lp(a) (Lipoprotein(a)) and Hepatic LPA Gene Expression Levels With Cardiovascular Outcomes: Mendelian Randomization and Observational Analyses.Semantic proximity Read ↗

Lipoprotein(a): more interesting than ever after 50 years.Semantic proximity Read ↗

The relationship between lipoprotein(a) and risk of cardiovascular disease: a Mendelian randomization analysis.Semantic proximity Read ↗

Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factorSemantic proximity Read ↗

Associations of Genetically Predicted Lp(a) (Lipoprotein [a]) Levels With Cardiovascular Traits in Individuals of European and African Ancestry.Semantic proximity Read ↗

Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart DiseaseSemantic proximity Read ↗

Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels.Semantic proximity Read ↗

Proteomic Insights into Lp(a) Cardiovascular Mechanisms: A Mendelian Randomization StudySemantic proximity Read ↗

[Lipoprotein(a) - the hereditary risk factor for cardiovascular disease].Semantic proximity Read ↗

A potentially underestimated predictor of coronary artery disease risk: The ApoB/ApoA1 ratioSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.